Strategic Expansion TD2 Oncology is expanding into Europe as of 2024 and has recently formed partnerships with Minerva Imaging and Panome Bio, signaling a growth trajectory and new regional capabilities that can be leveraged to offer integrated translational oncology services to European biopharma and biotech clients.

Omics Driven Rooted in translational genomics from TGen with omics-driven approach, TD2 offers unique clinical strategies that align with biopharma needs for multi-omics insights, enabling targeted preclinical and translational programs that can differentiate proposals to potential clients.

Strategic Hires Recent executive hires including a Senior VP of Strategic Solutions and a President of Business Operations indicate a focus on scalable solutions, enterprise-level partnerships, and improved how TD2 positions and negotiates large CRO engagements.

Radiopharma Fit Partnership with Minerva Imaging and expansion of radiopharmaceutical development support suggest a capability to handle advanced imaging and radiopharma programs, presenting cross-sell opportunities to clients pursuing diagnostic and theranostic pipelines.

Preclinical Clinical Synergy Acquisition of Flow Contract Site Laboratory and a strong preclinical-to-clinical trajectory position TD2 to offer integrated preclinical, regulatory, and clinical services, enabling bundled proposals to sponsors seeking end-to-end translational development.